

General information about company

| | |
|---|---|
| Scrip code* | 524404 |
| NSE Symbol* | MARKSANS |
| MSEI Symbol* | NOTLISTED |
| ISIN* | INE750C01026 |
| Name of company | Marksans Pharma Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 12-08-2025 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 24-07-2025 |
| Description of presentation currency | INR |
| Level of rounding | Millions |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Single segment |
| Description of single segment | Pharmaceutical Formulation |
| Start date and time of board meeting | 12-08-2025 11:45 |
| End date and time of board meeting | 12-08-2025 13:10 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes |
| No. of times funds raised during the quarter | 1 |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No The Company has not defaulted on loans and debt securityand hence the disclosure is not applicable. |

Financial Results - Ind-AS

| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|--|----------------|
| Date of start of reporting period | 01-04-2025 | 01-04-2025 | |
| Date of end of reporting period | 30-06-2025 | 30-06-2025 | |
| Whether results are audited or unaudited | Unaudited | Unaudited | |
| Nature of report standalone or consolidated | Standalone | Standalone | |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | | |
| 1 | Income | | |
| | Revenue from operations | 3197.34 | 3197.34 |
| | Other income | 20.1 | 20.1 |
| | Total income | 3217.44 | 3217.44 |
| 2 | Expenses | | |
| (a) | Cost of materials consumed | 1452.77 | 1452.77 |
| (b) | Purchases of stock-in-trade | 227.98 | 227.98 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | -32.91 | -32.91 |
| (d) | Employee benefit expense | 279.04 | 279.04 |
| (e) | Finance costs | 3.02 | 3.02 |
| (f) | Depreciation, depletion and amortisation expense | 81.88 | 81.88 |
| (g) | Other Expenses | | |
| 1 | Other Expenses | 569.92 | 569.92 |
| | Total other expenses | 569.92 | 569.92 |
| | Total expenses | 2581.7 | 2581.7 |
| 3 | Total profit before exceptional items and tax | 635.74 | 635.74 |
| 4 | Exceptional items | 0 | 0 |
| 5 | Total profit before tax | 635.74 | 635.74 |
| 6 | Tax expense | | |
| 7 | Current tax | 145.38 | 145.38 |
| 8 | Deferred tax | 9.8 | 9.8 |
| 9 | Total tax expenses | 155.18 | 155.18 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | 0 |
| 11 | Net Profit Loss for the period from continuing operations | 480.56 | 480.56 |
| 12 | Profit (loss) from discontinued operations before tax | 0 | 0 |
| 13 | Tax expense of discontinued operations | 0 | 0 |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | 0 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0 | 0 |
| 16 | Total profit (loss) for period | 480.56 | 480.56 |
| 17 | Other comprehensive income net of taxes | -0.76 | -0.76 |
| 18 | Total Comprehensive Income for the period | 479.8 | 479.8 |
| 19 | Total profit or loss, attributable to | | |
| | Profit or loss, attributable to owners of parent | | |

| | | | | |
|------------|--|-------------------------------|--------|------------------------|
| | Total profit or loss, attributable to non-controlling interests | | | |
| 20 | Total Comprehensive income for the period attributable to | | | |
| | Comprehensive income for the period attributable to owners of parent | | | |
| | Total comprehensive income for the period attributable to owners of parent non-controlling interests | | | |
| 21 | Details of equity share capital | | | |
| | Paid-up equity share capital | 453.16 | 453.16 | |
| | Face value of equity share capital | 1 | 1 | |
| 22 | Reserves excluding revaluation reserve | | | |
| 23 | Earnings per share | | | |
| i | Earnings per equity share for continuing operations | | | |
| | Basic earnings (loss) per share from continuing operations | 1.06 | 1.06 | |
| | Diluted earnings (loss) per share from continuing operations | 1.06 | 1.06 | |
| ii | Earnings per equity share for discontinued operations | | | |
| | Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| | Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| iii | Earnings per equity share (for continuing and discontinued operations) | | | |
| | Basic earnings (loss) per share from continuing and discontinued operations | 1.06 | 1.06 | |
| | Diluted earnings (loss) per share from continuing and discontinued operations | 1.06 | 1.06 | |
| 24 | Debt equity ratio | | | Textual Information(1) |
| 25 | Debt service coverage ratio | | | Textual Information(2) |
| 26 | Interest service coverage ratio | | | Textual Information(3) |
| 27 | Disclosure of notes on financial results | Textual Information(4) | | |

Text Block

Textual Information(4)

Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation 33 of the SEBI Listing Obligation and Disclosure Requirements Regulations, 2015 the Regulation as amended and expressed an unmodified conclusion.

The standalone unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation.

The figures for the quarter ended 31 March 2025 represent the derived figures between the audited figures in respect of full financial year ended 31 March 2025 and the unaudited published yearto date figures up to 31 December 2024, being the date of the end of third quarter of the financial year, which were subjected to a limited review by the statutory auditor of the Company.

The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on Operating Segments

Other income, net includes net loss on foreign exchange differences amounting to 37.73 million for the quarter ended 30 June 2025 31 March 2025 net gain of 25.80 million; 30 June 2024 net gain of 26.11 million; year ended 31 March 2025: net gain of 194.80 million.

The above standalone unaudited financials results are available on the Company's website www.marksanspharma.com and stock exchanges websites, BSE www.bseindia.com and NSE www.nseindia.com, where the shares of the Company are listed.

Other Comprehensive Income

| | | | |
|---|--|------------|------------|
| | Date of start of reporting period | 01-04-2025 | 01-04-2025 |
| | Date of end of reporting period | 30-06-2025 | 30-06-2025 |
| | Whether results are audited or unaudited | Unaudited | Unaudited |
| | Nature of report standalone or consolidated | Standalone | Standalone |
| | Other comprehensive income [Abstract] | | |
| 1 | Amount of items that will not be reclassified to profit and loss | | |
| 1 | Remeasurements of the net defined benefit liabilities/assets | -1.01 | -1.01 |
| | Total Amount of items that will not be reclassified to profit and loss | -1.01 | -1.01 |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | -0.25 | -0.25 |
| 3 | Amount of items that will be reclassified to profit and loss | | |
| | Total Amount of items that will be reclassified to profit and loss | | |
| 4 | Income tax relating to items that will be reclassified to profit or loss | | |
| 5 | Total Other comprehensive income | -0.76 | -0.76 |

Details of Impact of Audit Qualification

| | | | |
|--|-----------------------------------|--|------------------------|
| Whether results are audited or unaudited | Unaudited | | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion | | |
| Auditor's opinion | | | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes | | |
| | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto |
| 1 | M S K A & Associates | Yes | 31-07-2027 |

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

| | |
|--|---------------------|
| Mode of Fund Raising | Preferential Issues |
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 18-01-2023 |
| Amount Raised | 3724 |
| Report filed for Quarter ended | 30-06-2025 |
| Monitoring Agency | Not applicable |
| Monitoring Agency Name, if applicable | |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | NA |
| Comments of the Audit Committee after review | NA |
| Comments of the auditors, if any | NA |

| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
|-----|---|-------------------------|---------------------|-----------------------------|----------------|--|--|
| 1 | The proceeds of the preferential issue are proposed to be used to strengthen the capital base and to enhance long term financial resources of the Company in order to fund expansion program of the Company | None | 3724 | 0 | 3553 | 0 | No Deviations. Further please note that the funds are not raised during this quarter, and the reporting of the Statement of Deviation and Variation is being made for the funds raised in prior periods as mentioned. |

Signatory Details

| | |
|-----------------------|--|
| Name of signatory | Harshvardhan Panigrahi |
| Designation of person | Company Secretary and Compliance Officer |
| Place | Mumbai |
| Date | 12-08-2025 |

